Gibson, P. G., Reddel, H., McDonald, V. M., Marks, G., Jenkins, C., Gillman, A., Upham, J., Sutherland, M., Rimmer, J., Thien, F., Katsoulotos, G. P., Cook, M., Yang, I., Katelaris, C., Bowler, S., Langton, D., Robinson, P., Wright, C., Yozghatlian, V., Burgess, S., Sivakumaran, P., Jaffe, A., Bowden, J., Wark, P. A. B., Yan, K. Y., Kritikos, V., Peters, M., Hew, M., Aminazad, A., Bint, M., & Guo, M. (2016). effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Internal medicine journal, 46(9), 1054–1062. http://access.bl.uk/ark:/81055/vdc_100036426286.0x00001b